Alto Neuroscience (NYSE:ANRO) Downgraded by Zacks Research to Strong Sell

Alto Neuroscience (NYSE:ANRO) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities analysts have also issued reports on the company. Wedbush raised their target price on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, Wolfe Research initiated coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Stock Down 1.5%

NYSE:ANRO opened at $26.81 on Wednesday. The company has a market cap of $940.76 million, a PE ratio of -11.08 and a beta of 1.04. Alto Neuroscience has a twelve month low of $2.97 and a twelve month high of $28.85. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $23.39 and its two-hundred day moving average is $21.46.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Analysts anticipate that Alto Neuroscience will post -3.01 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ANRO. AQR Capital Management LLC purchased a new stake in Alto Neuroscience in the 1st quarter worth approximately $52,000. Torren Management LLC acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $62,000. Invesco Ltd. purchased a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $67,000. Bridgeway Capital Management LLC increased its holdings in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at $198,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.